Skip to main content
. 2022 May 12;14:910261. doi: 10.3389/fnagi.2022.910261

Table 3.

Adjusted comparison of neuropsychological outcomes between changes from baseline at 4 and 12 weeks after intervention in patients with mild AD (n = 19).

Outcomes Control group (n = 9) Intervention group (n = 10) 4-week adjusted estimate (95% CI)a; P-value 12-week adjusted estimate (95% CI)a; P-value
Baseline Change from baseline at 4 weeks Change from baseline at 12 weeks Baseline Change from baseline at 4 weeks Change from baseline at 12 weeks
MMSE 19.78 (3.19) 0.89 (2.26) 0.33 (2.45) 17.80 (3.22) 0.60 (2.99) 1.40 (2.88) −0.5 (−3.3–2.3); 0.707 1.1 (−1.7–4.0); 0.423
ADAS-cog 19.39 (9.33) −1.07 (6.60) −1.70 (7.51) 21.93 (6.03) −2.44 (4.72) −5.04 (5.17) −0.7 (−6.3–4.9); 0.786 −3.3 (−10.1–3.5); 0.319
AVLT immediate recall 12.11 (5.73) −0.11 (2.89) 0.44 (2.40) 11.83 (4.99) 4.60 (4.77) 5.30 (5.42) 4.3 (0.3–8.4); 0.039 4.9 (0.4–9.4); 0.035
AVLT delay recall 2.00 (2.96) 0.67 (1.41) 1.00 (2.18) 1.00 (1.33) 0.00 (1.49) 1.80 (2.57) −0.7 (−2.2–0.8); 0.345 1.0 (−1.3–3.3); 0.383
CDT 9.22 (3.90) 0.22 (3.07) −0.67 (3.84) 9.10 (2.56) 1.60 (3.34) 1.00 (2.94) 0.8 (−2.4–3.9); 0.601 1.2 (−2.3–4.6); 0.479
ADCS-ADL 53.11 (8.81) −0.11 (3.72) 2.33 (6.24) 51.40 (9.67) 0.10 (6.40) 2.10 (8.60) 0.1 (−5.2–5.4); 0.968 −0.8 (−8.1–6.5); 0.817
GDS-30 7.11 (2.32) 1.44 (4.16) 2.33 (6.38) 5.40 (3.03) 0.10 (2.69) −0.70 (2.40) −1.8 (−5.4–1.7); 0.280 −3.4 (−8.4–1.5); 0.158
PSQI 6.73 (2.85) 1.33 (2.00) 1.56 (3.24) 6.10 (3.67) −0.2 (2.57) −0.4 (2.12) −1.8 (−4.1–0.5); 0.108 −1.9 (−4.7–0.8); 0.158
a

Controlling for age and sex.

MMSE, mini-mental state examination; ADAS-cog, Alzheimer's disease assessment scale–cognitive subscale; AVLT, auditory verbal learning test; CDT, clock drawing test; ADCS-ADL, Alzheimer's disease cooperative study–activities of daily living scale; GDS-30, 30-item geriatric depression scale; PSQI, Pittsburgh sleep quality index.